ArticleBlood advances2024

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Jad Othman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.